

1 **Safety, tolerability, and immunogenicity of a new SARS-CoV-2 recombinant Gamma variant**
2 **RBD-based protein adjuvanted vaccine, used as heterologous booster in healthy adults: a Phase**
3 **1 interim report.**

4 Karina A. Pasquevich^{a,b,*}, Lorena M. Coria^{a,b}, Ana Ceballos^c, Bianca Mazzitelli^c, Juan Manuel
5 Rodriguez^d, Agostina Demaría^{a,b}, Celeste Pueblas Castro^{a,b}, Laura Bruno^{a,b}, Lucas Saposnik^{a,b}, Melina
6 Salvatori^c, Augusto Varese^c, Soledad González^c, Veronica V. González Martínez^c, Jorge Geffner^c,
7 Diego Álvarez^{a,b}, Laboratorio Pablo Cassará R&D and CMC group for ARVAC-CG^{d,f}, Ethel Feleder^g,
8 Karina Halabe^g, Pablo E. Perez Lera^g, Federico Montes de Oca^f, Julio C. Vega^f, Mónica Lombardo^h,
9 Gustavo A. Yerino^g, Juan Fló^f, Juliana Cassataro^{a,b,*}.

10 **Author Affiliations:**

11 ^aInstituto de Investigaciones Biotecnológicas, Universidad Nacional de San Martín (UNSAM) –
12 Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET). San Martín (1650), Buenos
13 Aires, Argentina.

14 ^bEscuela de Bio y Nanotecnologías (EByN), Universidad Nacional de San Martín. San Martín (1650),
15 Buenos Aires, Argentina.

16 ^cInstituto de Investigaciones Biomédicas en Retrovirus y SIDA, INBIRS-CONICET, Facultad de
17 Medicina UBA, Buenos Aires, Argentina.

18 ^dFundación Pablo Cassará - Unidad de I+D de Biofármacos. Saladillo 2452 C1440FFX, Ciudad
19 Autónoma de Buenos Aires, Argentina.

20 ^eMinisterio de Salud de la Provincia de Buenos Aires, Buenos Aires, Argentina.

21 ^fLaboratorio Pablo Cassará – Unidad de I+D de Biofármacos. Saladillo 2452 C1440FFX, Ciudad
22 Autónoma de Buenos Aires, Argentina.

23 ^gFP CLINICAL PHARMA, Ciudad Autónoma de Buenos Aires, Argentina.

24 ^hNobeltri. Ciudad Autónoma de Buenos Aires, Argentina.

25 ***Corresponding Author:** Address correspondence to Karina A Pasquevich

26 kpasquevich@iib.unsam.edu.ar and to Juliana Cassataro: jucassataro@iib.unsam.edu.ar

27 **Keywords:** COVID-19 subunit vaccine, Gamma variant, Phase 1, SARS-CoV-2, heterologous

28 booster.

29

30 SUMMARY

31 Background

32 In view of the emergence of SARS-CoV-2 immune escape variants and evidence of waning immunity,
33 new immunisation strategies and variant-adapted vaccines are needed. Based on preclinical proof of
34 concept studies and requirement of variant-adapted and booster vaccines, the Gamma Variant RBD-
35 based ARVAC-CG vaccine was selected for a first clinical trial in humans.

36 Methods

37 Eighty participants (healthy adults, 18-55 years-old) were sequentially assigned to receive two (28
38 days apart) intramuscular doses of 25- μ g (n=60) or 50- μ g (n=20) of a Gamma RBD-based subunit
39 vaccine adjuvanted with aluminium hydroxide. The primary endpoint was safety. The secondary
40 objective was to describe the neutralising antibody response against the SARS-CoV-2 Ancestral strain
41 and several variants of concern (Gamma, Delta, Omicron BA.1 and Omicron BA.5) measured by a
42 live virus-based neutralisation assay. Cellular immune responses were studied as an exploratory
43 objective by an enzyme-linked immunospot (ELISpot) assay. This trial is registered in
44 ClinicalTrials.gov ([NCT05656508](#)).

45 Findings

46 The interim results from the ongoing phase 1 study are described. ARVAC-CG exhibited a satisfactory
47 safety profile, a robust and broad booster response of neutralising antibodies against the Ancestral
48 strain of SARS-CoV-2, the Gamma variant, and other VOCs (Delta, Omicron BA.1 and Omicron
49 BA.5) and a booster effect on T cell immunity.

50 Interpretation

51 ARVAC-CG is safe and highly immunogenic when used as booster in individuals previously
52 immunised with different COVID-19 vaccine platforms. These results warrant further clinical
53 evaluation of this vaccine candidate for boosting other COVID-19 vaccines.

54 **Funding**

55 Laboratorio Pablo Cassará S.R.L. (Argentina).

56 **Research in context**

57 **Evidence before this study**

58 Next-generation COVID-19 vaccines are based on a variant-adapted approach, using a strain other
59 than the parental strain of SARS-CoV-2 (Wuhan or D614G strain). It has been suggested that the use
60 of vaccines containing Beta spike protein may be an interesting strategy to acquire wider protection
61 against SARS-CoV-2 variants. The Beta variant has been tested as booster in different monovalent or
62 bivalent vaccine platforms. Indeed, Sanofi and GSK VidPrevtyn® Beta has recently been approved in
63 Europe representing the first protein-based next-generation COVID-19 booster vaccine. While the
64 receptor binding domain (RBD) of the spike protein of Gamma and Beta SARS-CoV-2 variants are
65 very similar, no clinical data on Gamma variant-based COVID-19 vaccines has been published so far.
66 Preclinical data in mice indicate that the Gamma variant-based vaccine is more immunogenic and
67 induces a broader nAb response than the ancestral RBD-based vaccine.

68 **Added value of this study**

69 To our knowledge, these is the first clinical trial reported from any monovalent Gamma variant RBD
70 protein adjuvanted vaccine used as heterologous booster of different primary series vaccine platforms.
71 Two different vaccine doses were tested, and both exhibited a good profile of safety, tolerability and
72 reactogenicity. ARVAC-CG as a single heterologous booster induced a significant increase of broad-
73 spectrum neutralising antibodies against Ancestral, Gamma, Delta, Omicron BA.1 and Omicron BA.5
74 variants of concern (VOCs), binding antibodies, and IFN- γ producing cells. All these immune
75 responses were significantly boosted in individuals primed with vaccines from different platforms.
76 Plasma from vaccinees receiving a heterologous booster with ARVAC-CG was superior to plasma
77 from BTN16b2 boosted individuals in neutralising Omicron BA.1 and BA.5 SARS-CoV-2 VOCs.

78 **Implications of all the available evidence**

79 Here, we present the available data from the phase I study of ARVAC-CG vaccine, involving healthy
80 adults who had previously received a complete primary vaccination schedule with a COVID-19
81 vaccine.

82 The positive safety and immunogenicity results of the ARVAC-CG vaccine candidate presented here
83 justify further evaluation of its immunogenicity against currently circulating SARS-CoV-2 VOCs in a
84 comprehensive Phase 2/3 trial. Further research is required to assess the antibody persistence over time
85 after a booster dose of ARVAC-CG.

86

87 INTRODUCTION

88 The severe acute respiratory virus 2 (SARS-CoV-2) was first identified in November 2020 and soon
89 thereafter, emerging new viral variants dramatically impacted the dynamics of Coronavirus disease
90 2019 (COVID-19) spread, globally. These virus variants are, in general, more contagious, and virulent
91 than previous strains. Moreover, some variants are capable of immunological and/or therapeutic
92 escape.^{1,2}

93 Numerous vaccines have been developed and proved effective to protect against severe disease,
94 hospitalization, and fatal outcomes.³⁻⁵ In Argentina, several platforms of COVID-19 vaccines have
95 been introduced, including inactivated vaccines (BBIBP-CorV), viral vectored vaccines (Sputnik V,
96 AZD1222, CanSino), and mRNA vaccines (BNT162b2 and mRNA-1273), resulting in a significant
97 coverage of the population with complete primary vaccine series.^{6,7} However, due to waning immunity
98 and emergence of highly transmissible immune escape viral variants, two-dose COVID-19 vaccination
99 programs may have not been enough to prevent breakthrough infections caused by these variants.^{8,9}
100 Clinical studies suggest that boosting with variant-adapted vaccines would optimise vaccine efficacy
101 (VE) inducing strong and broad immune responses.¹⁰⁻¹²

102 The pandemic has disproportionately affected low- and middle-income countries (LMICs), which
103 make up about 85% of the world population. Therefore, pandemic remains threat unless most people
104 get vaccinated. In response to the constraints imposed by the COVID-19 pandemic, and the limited
105 access of many Latin American countries to costly vaccines, Laboratorio Pablo Cassará S.R.L., an
106 Argentinian pharmaceutical company, launched a vaccine development program against SARS-CoV-
107 2. ARVAC-CG is an receptor binding domain (RBD) based protein aluminium hydroxide adjuvanted
108 vaccine candidate that was designed and produced entirely in Argentina to be used as booster or
109 primary vaccine against SARS-CoV-2. The vaccine is a variant-adapted vaccine based on the highly
110 immune evasive Gamma SARS-CoV-2 variant of concern (VOC). Non-clinical studies of this vaccine

111 prototype in mice indicated that the Gamma-variant vaccine-candidate is more immunogenic and
112 induces a broader nAb response than the Ancestral vaccine-candidate.¹³

113 In this interim report safety and immunogenicity data after a booster dose of ARVAC-CG vaccine
114 from an ongoing first in human phase 1 study are presented.

115

116 **METHODS**

117 **Trial design and oversight**

118 This trial is registered in ClinicalTrials.gov ([NCT05656508](#)). The trial was conducted at Clinical
119 Pharma (Clínica CIAREC, Intense Life S.A, Buenos Aires, Argentina). In this open-label, first-in-
120 human, dose-escalation, phase 1 clinical trial, eligible volunteers were healthy men and nonpregnant
121 women, aged 18 to 55, with a body-mass index of 18 to 30. Health status, assessed during the screening
122 period, was based on medical history and extensive clinical laboratory tests, vital signs, and physical
123 examination. Participants with a history of SARS-Cov-2 infection or COVID-19 within 60 days prior
124 to recruitment into the study, or who tested positive in real-time polymerase-chain-reaction (RT-PCR)
125 assay screening or worked in an occupation with high risk of exposure to SARS-CoV-2, as well as
126 those with an incomplete COVID-19 vaccine primary schedule or who had received a booster dose of
127 any COVID-19 vaccine, were excluded. All participants provided written informed consent before
128 enrolment in the trial. The trial protocol was approved on March 09, 2022, by the Ethic Committee in
129 Clinical Research of Centro de Estudios Infectológicos S.A., and by the Food and Drugs National
130 Regulatory Agency (Administración Nacional de Medicamentos, Alimentos y Tecnología Médica,
131 ANMAT), on March 22, 2022.

132 The study protocol was initiated on April 10, 2022. Twenty seven out of 107 volunteers (13 males, 14
133 females) were excluded for not complying with eligibility criteria. Participants were recruited between
134 April 28 and June 23, 2022, and sequentially assigned to one of two vaccine groups, one receiving a
135 25- μ g dose of ARVAC-CG (Group A) and the other a 50- μ g dose (Group B). Of the 80 volunteers
136 who received at least one intramuscular dose of ARVAC-CG in the deltoid, three were excluded 28
137 days after the first dose of the vaccine due to impossibility to complete the protocol for personal
138 reasons. Of the 77 remaining, 59 were inoculated with two 25- μ g vaccine doses, and 18 with two 50-

139 µg vaccine doses. Investigators, and laboratory personnel involved in assays were blind to assignment
140 until the end of the follow-up period (Figure 1).

141 Demographic characteristics of the participants are presented in Table 1. Missing data or deviations
142 from original protocol were infrequent and inconsequential.

143 Safety was assessed according to the scheme established in the Guidance for Industry, Toxicity
144 Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical
145 Trials.¹⁴ Solicited local and systemic adverse events (AE) were recorded during the first 7 days after
146 each dose of vaccine received, unsolicited events were recorded during the first 28 days after
147 vaccination, laboratory tests were carried out after 7 and 28 days of each dose. The following symptom
148 grading was used for local and systemic AE: grade 1 (mild) to grade 4 (potentially life-threatening).
149 All safety information collected was available to an external Independent Committee of Data Review
150 for continuous monitoring of any relevant AE and recommendations of modifying or interrupting the
151 protocol as necessary.

152 Causality assessment of AE was based on the standard definition and application of terms for vaccine
153 pharmacovigilance as stated by the Report of the CIOMS/WHO Working Group on Vaccine
154 Pharmacovigilance¹⁵.

155 The immunogenicity of ARAVAC CG was compared to 18 samples obtained during the COVID-19
156 serology surveillance strategy implemented by the Ministry of Health of the Province of Buenos Aires,
157 between 4 February and 31 March 2022. These were individuals with similar demographic
158 characteristics who received a heterologous booster with the Ancestral-based BNT16b2 mRNA
159 vaccine administered at least 3 months after a two-dose primary schedule (Appendix Table S1).

160 **SARS-CoV-2 Neutralisation assays**

161 Neutralisation assays were performed using live SARS-CoV-2 virus isolates. Serial dilutions of plasma
162 samples from 1/8 to 1/16384 were incubated 1 h at 37°C in the presence of Ancestral (B.1), Gamma,
163 Delta, or Omicron variants (BA.1 or BA.5) in Dulbecco's Modified Eagle Medium (DMEM), 2% foetal
164 bovine serum (FBS). Then, 50µL of the mixture were deposited over Vero cell monolayers for an hour
165 at 37°C (MOI, 0.01). Infectious medium was removed and replaced by DMEM, 2%-FBS. After 72 h,
166 cells were fixed with 4% paraformaldehyde (4°C, 20 min) and stained with crystal violet solution in
167 methanol. The cytopathic effect (CPE) on the cell monolayer was assessed visually. If damage to the
168 monolayer was observed in the well, it was considered manifestation of CPE and the neutralisation
169 titre was defined as the highest serum dilution that prevented any CPE.

170 The nAb titres were transformed to international units per ml (IU/ml) by the inclusion in each plate of
171 a secondary standard that was calibrated with the WHO international standard (NIBSC code: 20/268)
172 following the WHO procedures manual.¹⁶

173 **SARS-CoV-2 antibody ELISA**

174 Antibodies against SARS-CoV-2 spike protein or RBD were detected using established, commercially
175 available, two-step ELISAs COVIDAR,¹⁴ or SARS-CoV-2 (RBD) total Ab ELISA from DRG
176 International (DRG Inc, Springfield, NJ 07081 USA). The immunoglobulin G (IgG) concentration of
177 each sample, expressed in Binding Antibody Units/mL (BAU/mL) was calculated by extrapolation of
178 the optical density at 450 nm (OD450) on a calibration curve built using serial dilutions of the WHO
179 International Standard for anti-SARS-CoV-2 immunoglobulin.

180 **ELISpot**

181 The T-cell mediated immune response against the SARS-CoV-2 RBD was assessed after the *in vitro*
182 peptide stimulation of peripheral blood mononuclear cells (PBMC), followed by IFN-γ and IL-4
183 enzyme-linked immune absorbent spot (IFN-γ and IL-4 ELISpot, BD Biosciences). A peptide pool of

184 overlapping SARS-CoV-2 peptides, encompassing the SARS-CoV-2 spike RBD covering the Gamma
185 variant was used in the assay (JPT Peptide Technologies GmbH, Germany).

186 **Statistical analysis**

187 Variables are reported as absolute numbers, percentages, means, medians, and interquartile range
188 (IQR), or geometric means and 95% confidence intervals (CI). Nonparametric statistical tests were
189 used to analyse differences in categorical variables. Immunogenicity response was assessed by means
190 of nAb geometric mean titres (GMTs), and seroconversion rates. Seroconversion was defined as a
191 change in value from below the lower limit of detection (LLOD) to at least 4 or 10 times above, or an
192 increase by a factor of at least four or ten if the baseline value was greater than or equal to the LLOD
193 in comparison to the pre-vaccination baseline value. Differences in mean, geometric mean, or
194 percentage values between groups and among prior vaccine platforms were assessed by means of
195 Mann Whitney u test, Wilcoxon pair-matched test, Kruskal-Wallis test with post hoc Dunn's for
196 multiple comparisons, Fisher exact test, or Chi square distribution, as appropriate. 95% CI were
197 calculated using the Wilson/Brown method. No assumptions were made for missing data. Statistical
198 analyses were done using GraphPad Prism v8.4.2 (GraphPad Software, San Diego, CA), Two-sided P
199 values <0.05 were considered statistically significant.

200 **Role of the funding source**

201 Laboratorio Pablo Cassará, in collaboration with the other authors, had a role in the design and
202 supervision of the study.

203 **RESULTS**

204 **Population characteristics and local and systemic adverse events**

205 The flowchart of the study is shown in figure 1. Demographic characteristics of the participants are
206 presented in table 1. Vaccination with ARVAC-CG was well tolerated, with mild-to-moderate
207 reactogenicity profiles (Figure 2A). Overall, solicited local AE were more frequently noticed after the
208 first dose of the vaccine than after the second. At least one local AE was observed in 68·3% of Group
209 A volunteers (25-µg vaccine) after the first administration and in 47·5% following the second
210 ($p=0\cdot026$). In group B (50-µg vaccine), 60·0% of volunteers reported at least one local AE after the
211 first injection whereas 27·8% following the second ($p=0\cdot0585$) (Table 2).

212 The most frequent local AE were discomfort/tenderness and pain at injection site in both groups
213 (Figure 2A). All reactions were transient and did not present complications.

214 Systemic AE were less common. Reported frequency of solicited/unsolicited systemic AEs, was not
215 significantly different between the first and second doses for both groups. In Group A, 33·3% and
216 35·6% of the volunteers reported at least one systemic AE after the first- and the second administration,
217 respectively ($p=0\cdot848$), while in Group B, 40·0% and 22·2% of the volunteers reported at least one
218 systemic AE after each dose, respectively ($p=0\cdot485$) (Table 2).

219 The most frequent systemic AEs were drowsiness, headache, myalgia, and fatigue (Figure 2B). Only
220 1 case of fever ($38\cdot3^{\circ}\text{C}$) lasting 1 day was reported. Of note, 89·9% of reported AE were grade 1 and
221 there was no grade 3 or more severe AE (Table 2).

222 No abnormal laboratory values were reported to be clinically significant. There were no serious AEs,
223 deaths, or withdrawals due to an AE during the study. No cases of Guillain-Barré syndrome,
224 thromboembolic events, myocarditis or pericarditis, or other AE of special interest have been reported.

225 **Immunogenicity results**

226 Immune responses presented in this interim report were evaluated after a single ARVAC-CG booster
227 administration. A significant increase of the nAb titres against all the five SARS-CoV-2 VOCs

228 analysed was observed in both ARVAC-CG vaccine cohorts after 14 days, compared to pre-
229 vaccination titres ($P < 0.0001$) (Figure 3). ARVAC-CG 25- μ g dose induced a 12.6 (95% CI, 8.8–17.9),
230 16.6 (95% CI, 11.8–23.4), 11.3 (95% CI, 7.8–16.5), 12.8 (95% CI, 9.2–18.0), and 8.6 (95% CI, 6.1–
231 12.0) geometric mean fold rise (GMFR) in nAb titres against Ancestral, Gamma, Delta, Omicron BA.1
232 or Omicron BA.5 variants of SARS-CoV-2, respectively (Figure 3A). Additionally, immunisation
233 with the 50- μ g dose induced a GMFR of 29.9 (95% CI, 12.6–70.6), 30.9 (95% CI, 13.4–71.5), 18.4
234 (95% CI, 8.2–41.1), 29.9 (95% CI, 13.0–68.3), and 13.0 (95% CI, 6.0–28.4) in nAb titres against
235 Ancestral, Gamma, Delta, Omicron BA.1 or Omicron BA.5 variants of SARS-CoV-2, respectively
236 (Figure 3B). Of note, GMFR of nAb titres against Ancestral and Omicron BA.1 variants were
237 significantly higher in Group B than in Group A ($P = 0.0448$ and $P = 0.0271$, respectively) (Appendix
238 table S2).

239 After 14 days of a booster with ARVAC-CG the 4 \times -seroconversion rates for the Ancestral SARS-
240 CoV-2 strain were 88.3 % (95% CI, 77.8–94.2) in the 25- μ g cohort and 90.0% (95% CI, 69.9–98.2)
241 in the 50- μ g cohort. Whereas the corresponding 4 \times -seroconversion rates were 90.0% (95% CI, 79.8–
242 95.3) and 85% (95% CI, 64.0–94.8) against the Gamma VOC, 80.0% (95% CI, 68.2–88.2) and 85.0%
243 (95% CI, 64.0–94.8) for Delta VOC, 93.3% (95% CI, 84.1–97.4) and 85.0% (95% CI, 64.0–94.8) for
244 Omicron BA.1 VOC, and 80.0% (95% CI, 68.2–88.2) and 80.0% (95% CI, 58.4–91.9) for Omicron
245 BA.5 VOC, respectively (Appendix table S2).

246 Fourteen days after boosting, 4 \times -seroconversion rates for all tested variants were similar in both
247 groups, while 10 \times -seroconversion rates for Omicron BA.1 VOC were significantly higher in the 50-
248 μ g cohort (Appendix table S2).

249 Based on pre-existing anti-N IgG titres and/or previous history of COVID-19, individuals were
250 stratified into two populations: seronegative individuals with no previous COVID-19 history and
251 seropositive and/or with previous history of COVID-19 individuals. Both populations developed

252 similar nAb GMTs against Ancestral, Gamma, Delta, Omicron BA.1 and Omicron BA.5 after 14 days
253 of ARVAC GC booster. Moreover, GMFR from baseline were similar for groups A and B (Appendix
254 Figure S1).

255 No significant differences were found in nAb responses and seroconversion rates between female or
256 male volunteers, except for the 4×-seroconversion rate in nAbs against Delta VOC (Appendix table
257 S3).

258 When volunteers were subdivided regarding the primary vaccination received, a significant increase
259 in the nAb GMTs against the different viral variants was observed in all previously vaccinated
260 subgroups (Figure 4).

261 Similar results were observed at 28 days post-booster vaccination with ARVAC-CG (Appendix Figure
262 S2 and table S4). Levels of anti-RBD and anti-spike antibodies raised significantly after 28 days with
263 respect to baseline levels in both study groups (Appendix Figure S3).

264 To preliminarily assess the comparative immunogenicity of ARAVAC GC, nAb GMTs and GMFR
265 were compared with those in samples from a cohort of individuals out of the protocol, with similar
266 demographic characteristic, who had received a heterologous booster dose with the Ancestral-based
267 BNT16b2 mRNA vaccine. Baseline nAb GMTs against the five viral variants in both ARVAC-CG
268 cohorts were similar to those observed before the booster with BNT16b2 ($P>0.05$) (Figure 5A-E).

269 After 14 or 28 days the nAb GMTs against the Ancestral SARS-CoV-2 in group A were similar to that
270 achieved after BNT16b2 booster (Figure 5A). However, nAb GMTs against Gamma, Delta, Omicron
271 BA.1, and Omicron BA.5 were significantly higher in group A than those reached in BNT16b2 boosted
272 individuals (Figure 5B-E). Similarly, in group B nAb GMTs against Gamma VOC after 14 days of
273 booster and against Omicron BA.1 and Omicron BA.5 VOCs at all tested timepoints were significantly
274 higher to the corresponding nAb GMTs in BNT16b2 boosted individuals (Figure 5B, D, and E).

275 While GMFR in nAb titres against Ancestral, Gamma and Delta VOCs after a booster dose with
276 BNT16b2 were similar to those elicited in the ARVAC-CG cohorts ($P>0.05$), GMFR of nAb titres
277 against Omicron BA.1 and BA.5 were significantly lower in the BNT16b2- than in the ARVAC-CG
278 boosted individuals (Figure 5F).

279 Transformation of nAb titres to IU/ml, allowed the evaluation of the percentage of participants with
280 nAb levels associated with high VE. In group A, rates of participants with nAb levels higher than of
281 947 IU/ml before the booster were 26.7 % (95% CI 39.0, 17.1), 3.3 % (95% CI 11.4, 0.6), 6.7 %
282 (95% CI 15.9, 2.6), and 1.7 % (95% CI 8.9, 0.1) for the Ancestral, Gamma, Delta, and Omicron BA.1
283 SARS-CoV-2 VOCs, respectively. These rates raised significantly after 14 days of having received
284 the booster to reach 83.3 % (95% CI 90.7, 72.0), 80.0 % (95% CI 88.2, 68.2), 60.0 % (95% CI 71.4,
285 47.4), and 78.3 % (95% CI 86.9, 66.4) for each viral variant, respectively. Likewise, in group B the
286 proportion of participants with nAb levels higher than 947 IU/ml raised significantly from 15.0 %
287 (95% CI 5.2, 36.0), 0.0 % (95% CI 0.0, 16.1), 5.0 % (95% CI 0.3, 23.6), and 10.0 % (95% CI 1.8,
288 30.1) for the Ancestral, Gamma, Delta, and Omicron BA.1 SARS-CoV-2 VOCs respectively at
289 baseline, to 80.0 % (95% CI 58.4, 91.9), 70.0 % (95% CI 48.1, 85.5), 45.0 % (95% CI 25.8, 65.8),
290 and 95.0 % (95% CI, 76.4, 99.7) for each viral variant, respectively. (Appendix Figure S4A-B).

291 A significant increase in the frequency of IFN- γ producing cells upon *in vitro* re-stimulation with
292 SARS-CoV-2 RBD peptide pools was observed in both ARVAC-CG cohorts in comparison with the
293 levels observed before the booster dose. In addition, a slight increase of IL-4 producing cells was
294 observed after the booster in group A participants (Figure 6). Interestingly, booster vaccination with -
295 25- μ g or 50- μ g of ARVAC-CG led to increases in antigen-specific cellular immune responses in
296 individuals primed with different vaccine platforms (Appendix Figure S5).

297 **Discussion**

298 The main findings of this study are that the vaccine candidate ARVAC-CG when given as a booster
299 dose is well tolerated and induces a robust and broad nAb response against several SARS-CoV-2
300 VOCs.

301 The interim results of this phase 1 study indicate that ARVAC-CG vaccine given to individuals who
302 previously received a complete primary vaccination regimen has a clinically acceptable safety and
303 reactogenicity profile for both antigen doses (25- μ g and 50- μ g).

304 Immunogenicity results indicate that ARVAC-CG as a booster dose induces a sharp increase of
305 broadly nAb titres against the Ancestral SARS-CoV-2 strain, the Gamma SARS-CoV-2 VOC, which
306 is the vaccine prototype strain, as well as against antigenic distant SARS-CoV-2 VOCs like Delta,
307 Omicron BA.1 and Omicron BA.5. Moreover, the ARVAC-CG 50- μ g dose outperformed the 25- μ g
308 dose in terms of nAb titres reached against the Ancestral and Omicron BA.1 viral variants and 10 \times -
309 seroconversion rates in nAb against Omicron BA.1. The booster effect of ARVAC-CG vaccine was
310 evident despite the variety of immunisation schemes received by the per protocol included population.

311 With the emergence of new VOCs it is clear that breakthrough infections can occur in vaccinated
312 persons, including those with previous SARS-CoV-2 infection.^{17,18} Therefore, the capability to boost
313 the immune responses in individuals with a previous history of infection becomes critical, enhancing
314 protection against COVID-19 and post-COVID conditions.¹⁹ The results of this study highlight the
315 potential benefit of the ARVAC-CG vaccine for all populations regardless of their prior COVID-19
316 serological status.

317 The performance of the ARVAC-CG booster dose regarding nAb GMTs and GMFR, was similar to
318 that of the BNT16b2 booster against Ancestral and Delta VOCs, but better for Gamma, Omicron BA.1
319 and BA.5 VOCs. Similarly, booster shots with Beta variant-based vaccines elicit broad nAb responses
320 against the Ancestral, the Beta and the Omicron BA.1 VOC, which were higher in terms of nAb GMT
321 or GMFR than that elicited by the Ancestral prototype vaccines, or a homologous booster with

322 BNT16b2.^{10,20,21} Results presented in this work suggest that a booster with ARVAC-CG increases the
323 breadth of the nAb and are in agreement with non-clinical results of this vaccine formulation¹³.

324 Even though there are not well-established threshold values of nAb levels that correlate with protection
325 against symptomatic and asymptomatic SARS-CoV-2 infection, an increasing number of studies that
326 use standardised methods offer hints about the nAb levels that might be associated with protection.^{18,22-}
327 ²⁴ In this regard, nAb levels of ~100-120 IU/ml have been correlated with ~80% VE against
328 symptomatic infection, whereas nAb levels of ~900-1030 IU/ml correlate with ~90% VE against
329 symptomatic infection.²² Results presented here suggest that a booster with ARVAC-CG increases
330 significantly the proportion of individuals with nAb titres that correlate with high VE.

331 T-cell immunity is crucial to combat acute SARS-CoV-2 infection and for the development of long-
332 term immunity.²⁵ While antibody titres tend to wane rapidly and show limited neutralising activity to
333 newly arising VOCs, T-cell memory is largely conserved.²⁵ ARVAC-CG boosted T cell immunity,
334 which might contribute to eliminate virus-infected cells. Although it has been reported that durable
335 spike-specific T-cell responses after different COVID-19 primary vaccination regimens are not further
336 enhanced by an mRNA booster,²⁶ results presented here show that ARVAC-CG booster significantly
337 increases the proportion of antigen-specific IFN- γ and IL-4 producing T cells in individuals previously
338 vaccinated with different primary schemes.

339 One limitation to this study is the lack of randomization for volunteers' recruitment. Nevertheless,
340 despite the sequential study design, enrolment dates of the booster groups occurred within weeks of
341 each other, representing similar epidemiologic environments of circulating variants.

342 In this phase 1 study, safety was demonstrated after two ARVAC-CG administrations highlighting that
343 ARVAC-CG is safe. Immune responses presented were assessed only after 14 and 28 days of one
344 booster administration, however longer-term follow-up of immune responses will have to be studied
345 in a phase 2/3 study.

346 While both formulations of ARVAC-CG exhibited a favourable safety and reactogenicity profile
347 eliciting broadly nAb responses and T cell immunity against SARS-CoV-2, the 50- μ g dose
348 outperformed the 25 - μ g dose in certain of the immunogenicity variables evaluated. Therefore, it might
349 be appropriate to test the 50- μ g dose vaccine in a Phase 2/3 study to evaluate its safety, and
350 immunogenicity in a larger population. Selection of the 50- μ g vaccine dose may allow the testing of a
351 bivalent vaccine containing 25- μ g of Gamma-based antigen plus 25- μ g of Omicron BA.5-based
352 antigen to improve the response capacity, as part of a Phase 2/3 study, in accordance with the
353 recommendations from the advisory committee on immunisation practices for the use of bivalent
354 booster doses of COVID-19 vaccines to increase protection against circulating VOCs and to broaden
355 neutralisation to previous and potentially yet-to-emerge variants.²⁷

356 There is a need for widespread immunisation programs with new generation of COVID-19 booster
357 vaccines which provide a wide breadth of protection against constantly emerging SARS-Cov-2
358 variants. Nonetheless, LMICs lag far behind in this effort due to limitations in affordability and
359 accessibility to vaccines. Hence, developments such as ARVAC GC may offer an opportunity to
360 overcome some of these challenges and improve response capacity of many countries, worldwide.

361

362 **Laboratorio Pablo Cassará R&D and CMC group:**

363 Sabrina A del Priore; Andrés C. Hernando Insua, Ingrid G. Kaufmann; Adrián Di María; Adrián
364 Góngora; Agustín Moreno; Susana Cervellini; Blasco Martin; Esteban Ali; Romina Albarracín;
365 Barsanti Bruno; Fernando Toneguzzo, Guillermina Sasso, Sebastian Stamer; Regina Cardoso and
366 Alejandro Chajet.

367 **Contributors**

368 JC, ML, JCV, FMO, JMR, JF, KAP, and LMC conceptualized and designed the study. KAP, LMC
369 and JC wrote and edited the manuscript. ML, FMO and JMR were responsible for project
370 administration. JC, KAP, LMC, ML, and JF, accessed, verified, and analysed the data, and generated
371 the interim report. EF is the study site scientific director and supervised the study. GAY is a study site
372 principal investigator. KH, GAY, and PEPL were responsible for the site work including the
373 recruitment, follow up, and data collection. BM, MS, AD, CPC, LS, LB performed immunogenicity
374 experiments. AC, AV, and JG contributed to the performance and analysis of neutralizing antibody
375 assays. SG, VVGM, and EE provided the plasma samples from individuals boosted with authorized
376 vaccines. JMR, JCV, FMO and LPC R&D and CMC Group were responsible for R&D for chemistry,
377 manufacture and controls of antigen and study products. JCV and FMO provided regulatory oversight.
378 ML was responsible for the overall supervision of the study and monitored the trial. All authors
379 contributed to data interpretation, review, and editing of this manuscript. All authors have read and
380 approved the final version of the manuscript.

381 **Declaration of interests**

382 JMR, LPC R&D and CMC Group, FMO, JCV are employees of Laboratorio Pablo Cassará S.R.L.,
383 which developed the vaccine and funded the trial. ML and JF are external consultants and received
384 honoraria from Laboratorio Pablo Cassará S.R.L. All other authors declare no competing interests.

385 Acknowledgments

386 We thank the trial volunteers for their contribution and commitment to vaccine research. We are
387 thankful to the staff of Laboratorio Pablo Cassará for their essential contribution to the development,
388 scaling, manufacture, control and stability study of the clinical batches of ARVAC-CG antigen and
389 vaccine: Krum, Valeria; Drehe, Ignacio; Zurvarra, Francisco; Baque, Jonathan; Payes, Cristian;
390 Heinrich, Brenda; Gambone, Melisa; Descoins, Horacio; De Nichilo, Analía; Sidabra, Johanna;
391 Licausi, Mariana; Cortez, Christian; Roman, María Victoria; Villar, Alejandra; Diaz, Sebastián;
392 Frattolillo, Matías; Mestre, Diego; Gonzalo, Javier; Maluvini, Ernesto; Sperandini, Cecilia; Farre,
393 Paola; Trovato, Fernando; Strada, Ariel; Cocciolo, Giovanna; and Privitera, Anabella. We additionally
394 thank Roberto Debagg for giving valuable advice during to the design and completion of the clinical
395 trial. We thank Daniela Hozbor for the access to the samples obtained during the COVID-19 serology
396 surveillance strategy implemented by the Ministry of Health of the Province of Buenos Aires. We
397 thank Florencia Quiroga, Gabriela Turk and Natalia Laufer for performing T cell stimulation assays
398 by ELISpot at Instituto de Investigaciones Biomédicas en Retrovirus y SIDA, INBIRS-CONICET,
399 Buenos Aires, Argentina. We also thank Jaime Torres who provided medical writing support. We
400 thank Elisa Estenssoro of the Ministry of Health of the Province of Buenos Aires for critical review of
401 the manuscript. We are grateful to Dr. Ángela Spanguolo de Gentile, Dr. Pablo Bonvehí, and Dr. Hugo
402 Krupitzki who are members of the external Independent Committee of Data Review for their
403 dedication and continuous invaluable advice.

404


405 References

- 406 1. Chi W-Y, Li Y-D, Huang H-C, et al. COVID-19 vaccine update: vaccine effectiveness, SARS-CoV-2 variants,
407 boosters, adverse effects, and immune correlates of protection. *Journal of Biomedical Science* 2022; **29**(1).
- 408 2. Shrestha LB, Foster C, Rawlinson W, Tedla N, Bull RA. Evolution of the SARS-CoV-2 omicron variants BA.1
409 to BA.5: Implications for immune escape and transmission. *Rev Med Virol* 2022; **32**(5): e2381.
- 410 3. Martinez-Flores D, Zepeda-Cervantes J, Cruz-Resendiz A, Aguirre-Sampieri S, Sampieri A, Vaca L. SARS-
411 CoV-2 Vaccines Based on the Spike Glycoprotein and Implications of New Viral Variants. *Front Immunol* 2021; **12**:
412 701501.
- 413 4. Pollet J, Chen WH, Strych U. Recombinant protein vaccines, a proven approach against coronavirus pandemics.
414 *Adv Drug Deliv Rev* 2021; **170**: 71-82.
- 415 5. Heidary M, Kaviar VH, Shirani M, et al. A Comprehensive Review of the Protein Subunit Vaccines Against
416 COVID-19. *Front Microbiol* 2022; **13**: 927306.
- 417 6. Pascuale CA, Varese A, Ojeda DS, et al. Immunogenicity and reactogenicity of heterologous immunization
418 against SARS CoV-2 using Sputnik V, ChAdOx1-S, BBIBP-CorV, Ad5-nCoV, and mRNA-1273. *Cell Rep Med* 2022;
419 **3**(8): 100706.
- 420 7. Rearte A, Castelli JM, Rearte R, et al. Effectiveness of rAd26-rAd5, ChAdOx1 nCoV-19, and BBIBP-CorV
421 vaccines for risk of infection with SARS-CoV-2 and death due to COVID-19 in people older than 60 years in Argentina:
422 a test-negative, case-control, and retrospective longitudinal study. *Lancet* 2022; **399**(10331): 1254-64.
- 423 8. Cele S, Jackson L, Khoury DS, et al. Omicron extensively but incompletely escapes Pfizer BNT162b2
424 neutralization. *Nature* 2022; **602**(7898): 654-6.
- 425 9. Kuhlmann C, Mayer CK, Claassen M, et al. Breakthrough infections with SARS-CoV-2 omicron despite mRNA
426 vaccine booster dose. *Lancet* 2022; **399**(10325): 625-6.
- 427 10. Launay O, Cachanado M, Luong Nguyen LB, et al. Immunogenicity and Safety of Beta-Adjuvanted
428 Recombinant Booster Vaccine. *N Engl J Med* 2022; **387**(4): 374-6.
- 429 11. Choi A, Koch M, Wu K, et al. Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in
430 healthy adults: an interim analysis. *Nat Med* 2021; **27**(11): 2025-31.
- 431 12. Branche AR, Rouphael NG, Diemert DJ, et al. SARS-CoV-2 Variant Vaccine Boosters Trial: Preliminary
432 Analyses. *medRxiv* 2022.
- 433 13. Coria LM, Rodriguez JM, Demaria A, et al. A Gamma-adapted recombinant subunit vaccine induces broadly
434 neutralizing antibodies against SARS-CoV-2 variants and protects mice from SARS-CoV-2 infection. *bioRxiv* 2023:
435 2023.01.03.522213.
- 436 14. FDA. Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine
437 Clinical Trials. In: U.S. Department of Health and Human Services., editor. Guidance for Industry; 2007.
- 438 15. CIOMS/WHO. Definition and Application of Terms for Vaccine Pharmacovigilance. Geneva: Working Group
439 on Vaccine Pharmacovigilance. Council for International Organizations of Medical Sciences (CIOMS), World health
440 organization (WHO), 2012.
- 441 16. World Health Organization. WHO manual for the establishment of national and other secondary standards for
442 antibodies against infectious agents focusing on SARSCoV2. World Health Organization; 2022.
- 443 17. Carazo S, Skowronski DM, Brisson M, et al. Protection against omicron (B.1.1.529) BA.2 reinfection conferred
444 by primary omicron BA.1 or pre-omicron SARS-CoV-2 infection among health-care workers with and without mRNA
445 vaccination: a test-negative case-control study. *Lancet Infect Dis* 2022.
- 446 18. Khoury DS, Cromer D, Reynaldi A, et al. Neutralizing antibody levels are highly predictive of immune
447 protection from symptomatic SARS-CoV-2 infection. *Nat Med* 2021; **27**(7): 1205-11.
- 448 19. Gilbert PB, Montefiori DC, McDermott AB, et al. Immune correlates analysis of the mRNA-1273 COVID-19
449 vaccine efficacy clinical trial. *Science* 2022; **375**(6576): 43-50.
- 450 20. Chalkias S, Eder F, Essink B, et al. Safety, immunogenicity and antibody persistence of a bivalent Beta-
451 containing booster vaccine against COVID-19: a phase 2/3 trial. *Nat Med* 2022; **28**(11): 2388-97.
- 452 21. Lien CE, Liu M-C, Wang N-C, et al. A Phase I, Prospective, Randomized, Open-labeled Study to Evaluate the
453 Safety, Tolerability, and Immunogenicity of Booster Dose with MVC-COV1901 or MVC-COV1901(Beta) SARS-CoV-2
454 Vaccine in Adults. Cold Spring Harbor Laboratory; 2022.
- 455 22. Feng S, Phillips DJ, White T, et al. Correlates of protection against symptomatic and asymptomatic SARS-CoV-
456 2 infection. *Nat Med* 2021; **27**(11): 2032-40.
- 457 23. Goldblatt D, Fiore-Gartland A, Johnson M, et al. Towards a population-based threshold of protection for
458 COVID-19 vaccines. *Vaccine* 2022; **40**(2): 306-15.
- 459 24. Fong Y, McDermott AB, Benkeser D, et al. Immune correlates analysis of the ENSEMBLE single
460 Ad26.COV2.S dose vaccine efficacy clinical trial. *Nat Microbiol* 2022; **7**(12): 1996-2010.
- 461 25. Wherry EJ, Barouch DH. T cell immunity to COVID-19 vaccines. *Science* 2022; **377**(6608): 821-2.
- 462 26. Maringer Y, Nelde A, Schroeder SM, et al. Durable spike-specific T-cell responses after different COVID-19
463 vaccination regimens are not further enhanced by booster vaccination. *Sci Immunol* 2022: eadd3899.

464 27. Rosenblum HG, Wallace M, Godfrey M, et al. Interim Recommendations from the Advisory Committee on
465 Immunization Practices for the Use of Bivalent Booster Doses of COVID-19 Vaccines - United States, October 2022.
466 *MMWR Morb Mortal Wkly Rep* 2022; 71(45): 1436-41.
467
468

469 **Figures**


470 **Figure 1**



471 **Figure 1. Subject disposition in Phase-1 study (consort diagram).** Trial profile showing the study groups,

472 number of participants, and vaccine dose received.


473 **Figure 2**



474

475 **Figure 2. Safety profile. (A)** Percentage of participants in each study group with the indicated injection site
 476 AEs up to 7 days after the first or the second injection. **(B)** Percentage of participants in each study group with
 477 the indicated systemic AEs recorded up to 28 days after each vaccine administration. Events were classified
 478 according to the FDA toxicity grading scale for healthy adult and adolescent volunteers enrolled in preventive
 479 vaccine clinical trials (Mild (Grade 1), Moderate (Grade 2), Severe (Grade 3), Potentially Life Threatening
 480 (Grade 4))¹⁴.

481 **Figure 3**



482

483 **Figure 3: Administration of ARVAC-CG booster increases the nAb titres against the Ancestral, Gamma, Delta,**

484 **Omicron BA.1 and Omicron BA.5 variants of SARS-CoV-2.** The nAb titres against the Ancestral, Gamma, Delta and

485 Omicron BA.1 and Omicron BA.5 variants of SARS-CoV-2 in plasma samples of individuals boosted with ARVAC-CG

486 25µg (A) or 50 µg (B) prior to the vaccine administration (d1) or after 14 days of booster administration (d14). Each point

487 represents the nAb titre of a volunteer at the indicated time point and against the depicted viral variant. The nAb geometric

488 mean titres (GMTs) and 95% CIs are shown as horizontal and error bars, respectively. The numbers depicted above the

489 individual points for each specified time point and viral variant represent the GMT. The fold increases in the GMT from


490 day 1 to day 14 (GMFR) for each specified variant are shown with a number followed by a ×. The dashed line represents

491 the positivity threshold on the Neutralisation assay. Statistical differences were analysed using the Wilcoxon pair-matched

492 test. Exact P values are depicted above the data sets that were compared.

493


494 **Figure 4**



496 **Figure 4: Administration of ARVAC-CG as booster increases the nAb titres against the Ancestral,**
497 **Gamma, Delta, Omicron BA.1 and Omicron BA.5 variants of SARS-CoV-2 in individuals with different**
498 **primary vaccinations schemes.** Neutralising antibody titres against the Ancestral (A), Gamma (B), Delta (C),
499 Omicron BA.1 (D) and Omicron BA.5 (E) variants of SARS-CoV-2 in plasma samples of individuals boosted
500 with ARVAC-CG 25 μ g (left panels) or 50 μ g (right panels) prior to the vaccine administration (d1) or after 14
501 days of booster administration (d14). Participants in each cohort were grouped according to the primary
502 vaccination scheme received (BBIBP-CorV (Sinopharm), ChAdOx1-S (Oxford AstraZeneca), rAd26/rAd5
503 (Sputnik V, Gamaleya Institute), Ad5-nCoV (CanSino), Ad26.CoV2.S (Janssen), rAd26/ChAdOx1-S
504 (heterologous vaccination regime Sputnik V Component 1/ Oxford AstraZeneca) or heterologous vaccination
505 regimens (ChAdOx1-S / mRNA1273 or BBIBP-CorV / BNT162b2). Each point represents the nAb titre of a
506 volunteer at the indicated time point and against the depicted viral variant. The nAb GMTs with 95% CIs are
507 shown as horizontal and error bars, respectively. The numbers depicted above the individual points for each
508 specified time point and viral variant represent GMT values. The fold increases in GMT values from day 1 to
509 day 14 (GMFR) for each specified variant are shown with a number followed by a \times . The dashed line represents
510 the positivity threshold on the Neutralisation assay. Statistical differences were performed using the Wilcoxon
511 pair-matched test. Exact P values are depicted above the data sets that were compared.

512

513 **Figure 5**




514

515 **Figure 5: Comparison of nAb GMT and GMFR after booster with ARVAC-CG or booster with BNT162b2**
 516 **in a contemporaneous boosted study.** Neutralising antibody titres against the Ancestral (A), Gamma
 517 (C), Delta (C), Omicron BA.1 (D) and Omicron BA.5 (E) variants of SARS-CoV-2 in plasma samples of individuals
 518 boosted with the indicated vaccine (ARVAC-CG 25µg, ARVAC-CG 50 µg or BNT162b2) prior to the vaccine
 519 administration (d1) or at the indicated days after booster administration (d14, d21, d28). Each point represents
 520 the nAb titre of a volunteer boosted with the indicated vaccine, at the indicated time point and against the
 521 depicted viral variant. The nAb GMTs and 95% CIs are shown as horizontal and error bars, respectively. The
 522 numbers depicted above the individual points for each specified time point and viral variant represent the GMTs.
 523 Statistical differences were analysed using the Kruskal-Wallis test followed by the Dunn’s multiple comparison
 524 test. Exact P values are depicted above the data sets that were compared. ns: P>0.05 (F) Fold increases in the
 525 GMT from day 1 to day 21 or 28 (GMFR) for each specified variant represented by a point and written with a
 526 number followed by a ×. The horizontal lines represent the 95% CIs. Statistical differences were analysed using

- 527 Kruskal-Wallis test followed by the Dunn's multiple comparison test. ns: $P > 0.05$, ★: $P < 0.05$; ★★: $P < 0.001$;
- 528 ★★ ★★: $P < 0.0001$

529 **Figure 6**



530

531 **Figure 6. ARVAC-CG booster induces significant increase of Th1-predominant cell response measured**
532 **by IFN- γ and IL-4 ELISpot after restimulation of PBMCs with RBD spanning peptide pool.** Before
533 booster administration (1d) and after 28 days (d28) of administration of ARVAC-CG 25 μ g (A) or 50 μ g (B)
534 dose, RBD specific cellular responses were measured by IFN- γ and IL-4 ELISpot in PBMCs. Shown are spot-
535 forming units (SFU) per 1×10^6 PBMCs producing IFN- γ and IL-4 after stimulation with-RBD peptide pool.
536 Bars indicate the mean, and error bars the SEM. Statistical analysis was performed by the Wilcoxon matched
537 pairs signed rank test. ****: $P < 0.0001$; *: $P < 0.05$; ns: $P > 0.05$.

538

539 **Tables**

540 **Table 1** Demographic Characteristics of the Participants in the ARVAC-F1-001 Trial at Enrolment.

Table 1. Demographic Characteristics of the Participants in the ARVAC-F1-001 Trial at Enrolment.				
Variable		ARVAC-CG 25-µg Group A	ARVAC-CG 50-µg Group B	Total
No. of participants		60	20	80
Sex	Male (N (%))	29 (48.3)	8 (40)	37 (46.3)
	Female (N (%))	31 (51.7)	12 (60)	43 (53.8)
Age (Median (IQR)^a)		32 (25-37.25)	27 (20.75-33.25)	31 (24-37)
Body-mass index (Median (IQR))		25.7 (22.9-27.8)	26.1 (21.1-27.4)	25.8 (22.9-27.8)
COVID-19 Primary Vaccine Platform	Sinopharm (N (%))	20 (33.3)	14 (70.0)	34 (42.5)
	Sputnik (N (%))	21 (35.0)	1 (5.0)	22 (27.5)
	AstraZeneca (N (%))	17 (28.3)	1 (5.0)	18 (22.5)
	CanSino (N (%))	1 (1.7)	0 (0)	1 (1.3)
	Janssen (N (%))	0 (0)	1 (5.0)	1 (1.3)
	Heterologous schedule (N (%))	1 (1.7)	3 (15.0)	4 (5.0)
Time (months) since last dose of primary immunisation schedule. (Median (IQR))		7.9 (6.2-8.7)	6.6 (4.9-8.1)	7.7 (6.0-8.4)
Prior COVID-19	No (N (%))	55 (91.7)	16 (80.0)	71 (88.8)
	Yes (N (%))	5 (8.3)	4 (20.0)	9 (11.3)
	Time (months) since infection (Median (IQR))	12.0 (4.9-20.3)	5.7 (5.6-5.9)	5.8 (5.3-12.0)

^a IQR: interquartile range.

541

542

543 Table 2

Table 2. Local and systemic adverse events: Incidence, frequency and severity by vaccine group and doses.								
Dose Administration	ARVAC-CG 25-µg Group A				ARVAC-CG 50-µg Group B			
	First or second (N = 60)	First (N = 60)	Second (N = 59)	P ^A	First or second (N = 20)	First (N = 20)	Second (N = 18)	P ^A
Participants with at least one local adverse event, incidence (frequency)								
Any grade	46 (76.7)	41 (68.3)	28(47.5)	0.026	12 (60.0)	12 (60.0)	5 (27.8)	0.0585
p^B					0.1606	0.5874	0.1785	
Grade 1	45 (75.0)	41 (68.3)	28 (47.5)	0.026	12 (60.0)	12 (60.0)	4 (22.2)	0.025
p^B					0.2555	0.5874	0.0995	
Grade 2	7 (11.7)	5 (8.3)	2 (3.4)	0.439	2 (10)	1 (5.0)	1 (5.6)	>0.999
p^B					>0.9999	>0.9999	0.5556	
Local adverse events overall frequency, N (%)^C								
Any	129 (100)	71 (100)	58 (100)		34 (100)	25 (100)	9 (100)	
Grade 1	117 (90.7)	62 (87.3)	55 (94.8)		31 (91.2)	24 (96)	7 (77.8)	
Grade 2	12 (9.3)	9 (12.7)	3 (5.2)		3 (8.8)	1 (4)	2 (22.2)	
Grade 3	0 (0)	0 (0)	0 (0)		0 (0)	0 (0)	0 (0)	
Grade 4	0 (0)	0 (0)	0 (0)		0 (0)	0 (0)	0 (0)	
Participants with at least one systemic adverse event, N (%)								
Any Grade	28 (46.7)	20 (33.3)	21 (35.6)	0.848	8 (40.0)	8 (40.0)	4 (22.2)	0.485
p^B					0.7958	>0.9999	0.3926	
Grade 1	28 (46.7)	19 (31.7)	21 (35.6)	0.700	8 (40)	7 (35)	4 (22.2)	0.485
p^B					0.6087	0.7887	0.3926	
Grade 2	6 (10)	4 (6.7)	4 (6.8)	>0.99	1 (5)	1 (5)	0 (0)	>0.99
p^B					0.3282	>0.9999	>0.9999	
Systemic adverse events overall frequency, N (%)^C								
Any	101 (100)	53 (100)	48 (100)		37 (100)	25 (100)	12 (100)	
Grade 1	90 (89.1)	48 (90.6)	42 (87.5)		34 (91.9)	22 (88)	12 (100)	
Grade 2	11 (10.9)	5 (9.4)	6 (12.5)		3 (8.1)	3 (12)	0 (0)	
Grade 3	0 (0)	0 (0)	0 (0)		0 (0)	0 (0)	0 (0)	
Grade 4	0 (0)	0 (0)	0 (0)		0 (0)	0 (0)	0 (0)	

Data are expressed as number of individuals, N (percentage, %) or median (interquartile range, IQR).
^A Exact P Value. First vs. Second dose. Fisher's exact test.
^B Exact P value. 25-µg vs 50-µg. Fisher's exact test.
^C Overall adverse events in the same study group.

544

545